Biolinq has completed its pivotal trial and submitted its wearable biosensor to the FDA for regulatory review.

The Series C funding supports Biolinq’s transition from development stage to commercial readiness following US pivotal trial completion and regulatory submission. Biolinq’s intradermal biosensor ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

The rapid evolution of smart sensing technology is leading to a comprehensive penetration of biosensing applications in the ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today ... we’re proud to offer the longest lasting wearable and most accurate CGM, giving people the knowledge ...

The company's prototypes highlight fully remote power transfer (charging over the air), biosensing ... radiation levels ...